CEO Eric Dube (Travere Therapeutics)

Retrophin no more: Shkre­li's lega­cy dis­ap­pears as for­mer com­pa­ny be­comes Tra­vere Ther­a­peu­tics

Retrophin is shed­ding the last of its ties to con­vict­ed “Phar­ma Bro” Mar­tin Shkre­li and his failed neu­ro­log­i­cal drug — with a name change.

“That name doesn’t re­flect who we are to­day, and the role that we want to play go­ing in­to the fu­ture. So we felt that it was be­fit­ting to have a name that every sin­gle one of us came to work and can iden­ti­fy with,” CEO Er­ic Dube told End­points News.

The biotech, which was found­ed in 2011 by Shkre­li, now goes by Tra­vere Ther­a­peu­tics, in­spired by the Latin roots of the words “path” (trac­tus) and “truth” (ver). Dube said the re­brand­ing has been in the works since he joined the com­pa­ny last year, and rep­re­sents “the tire­less jour­ney that many rare dis­ease fam­i­lies em­bark on to reach a di­ag­no­sis and ul­ti­mate­ly a treat­ment or cure.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.